Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

Sponsor
Children's Cancer and Leukaemia Group
Study ID
NCT00276692
Phase
PHASE2
Status
Completed

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
N/A - 19 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with newly diagnosed Ewing's sarcoma.

Key Dates

Start date
Aug 31, 2003
Status verified
Jun 2009
Primary completion
Sep 30, 2008
Completion
Jul 31, 2009

Study Design

Enrollment
35 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Response as measured by MRI following course 2

Related Studies